SEARCH SITE

VIRGINIA LAW PORTAL

SEARCHABLE DATABASES

ACROSS SESSIONS

Developed and maintained by the Division of Legislative Automated Systems.

2024 SESSION

  • | print version

SB 186 Wholesale prescription drug importation program; Sec. of Health and Human Resources to establish.

Introduced by: Suhas Subramanyam | all patrons    ...    notes | add to my profiles | history

SUMMARY AS PASSED SENATE:

Secretary of Health and Human Resources; work group; wholesale prescription drug importation programs; report. Directs the Secretary of Health and Human Resources to convene a work group to investigate wholesale prescription drug importation programs in other states and evaluate best practices for the establishment and application of such a program in the Commonwealth. The bill requires the Secretary of Health and Human Resources to provide a report to the Governor, the House Committees on Appropriations and Health and Human Services, and the Senate Committees on Finance and Appropriations and Education and Health by November 1, 2024.

SUMMARY AS INTRODUCED:

Secretary of Health and Human Resources; wholesale prescription drug importation program. Directs the Secretary of Health and Human Resources to establish a wholesale prescription drug importation program that complies with the requirements of federal law and to report annually by October 1 to the Governor and the Chairmen of the House Committees on Appropriations and Health, Welfare and Institutions and the Senate Committees on Finance and Appropriations and Education and Health on the wholesale prescription drug importation program. The bill also requires the Secretary to (i) convene a work group composed of relevant stakeholders to develop a plan for implementation of the wholesale prescription drug importation program and report the plan to the Governor and the Chairmen of the House Committees on Appropriations and Health, Welfare and Institutions and the Senate Committees on Finance and Appropriations and Education and Health by December 1, 2024, and (ii) seek such federal approvals, waivers, exemptions, or agreements as may be necessary to enable all covered entities enrolled in or eligible for the federal 340B Drug Pricing Program to participate in the wholesale prescription drug importation program to the greatest extent possible without jeopardizing their eligibility for the 340B Drug Pricing Program by July 1, 2025.